Needham & Company
-
Aquinox Announces Closing of $75.4 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Aquinox Pharma (AQXP) Prices 5.35M Common Stock Offering at $12.25/Share
-
Aquinox Prices Public Offering of Common Stock
-
Aquinox Pharma (AQXP) Plans Common Stock Offering
-
Aquinox Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Aquinox to Present at 2016 Annual Needham Healthcare Conference
-
Aquinox Pharmaceuticals Reports Third Quarter 2015 Financial Results
-
Aquinox Pharmaceuticals Reports Third Quarter 2015 Financial Results
-
Needham & Company Keeps Aquinox Pharma (AQXP) at 'Buy'; Failure of AQX-1125 in Atopic Dermatitis Won't Impact Model
-
UPDATE: Needham & Company Starts Aquinox Pharmaceutical (AQXP) at Buy
-
Notable Analyst Rating Changes 10/6: (CSAL) (FDX) (NUVA) Upgraded; (HPY) (CMA) (TDY) Downgraded
-
Aquinox Announces Closing of $98.0 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Aquinox Announces Closing of $98.0 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Aquinox Pharma (AQXP) 5.5M Offering Common Stock Prices at $15.50/Share
-
Aquinox Prices Public Offering of Common Stock
-
Aquinox Prices Public Offering of Common Stock
-
Aquinox Pharma (AQXP) Announces $75M Common Stock Offering
-
Aquinox Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Pre-Open Stock Movers 08/10: (AQXP) (VLTC) (INO) (PCP) Higher; (SYN) (JD) (FCX) Lower (more...)
-
Aquinox Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference

